RE002 T cell

RE002 T cell is a code name for an investigational autologous T-cell therapy. It likely refers to a genetically engineered T-cell product, but there is no evidence in the provided search results or current public domain sources that "RE002 T cell" corresponds to any approved, late-stage, or widely recognized clinical-stage drug as of May 2025. The naming convention suggests it could be a research-stage or preclinical candidate involving modified human T cells—possibly using chimeric antigen receptor (CAR) or engineered T-cell receptor (TCR) technology for cancer immunotherapy. However, no specific mechanism of action, target antigen, developer company, indication, or clinical trial information can be confirmed from available data.